Blog

Throughout 2023, our Fetal Bovine Serum (FBS) continues to prove again and again that it is a major contributor in meaningful research. With a number of citations in published research, you can count on the reliability and consistency of our FBS in your cell culturing projects. Now, we are giving back, by offering 10% off our Premium USA Origin FBS (cat. FBS001) through the end of November.

Our Premium USA Origin FBS is undoubtedly one of highest quality serums on the market and is equipped to culture all cell types. This serum has impressively low endotoxin levels, is triple 0.1 μm filtered, is free of virus and mycoplasma, and is our most frequently cited type of FBS. It really is no surprise to see how well it performed compared to its competitors - see the data for yourself here.

In case you were wondering, our Heat Inactivated Premium USA Origin FBS (cat. FBS001-HI) is also 10% off.

In the world of life sciences, successful cell culture is pivotal for achieving accurate and reproducible results. That's why finding a reliable and consistent source of Fetal Bovine Serum (FBS) is so important. With many research proven and affordable FBS options, choosing Neuromics FBS will ensure your desired growth of healthy, vibrant cells.

We firmly believe that the best way to demonstrate the quality of FBS is through results. Thanks to our many customers, we continue to wrack up references and citations from researchers.

Earlier this month, investigators from City of Hope used our heat-inactivated premium imported FBS (USDA approved) (cat. FBS002-HI) in cancer drug discovery research. The FBS was used to culture various neuroblastoma and breast cancer cell lines, along with HEK293T cells. Scientists identified a small molecule called AOH1996 that seemingly kills solid tumors while preserving healthy cells and causing no side effects.

We encourage you to read the full publication to learn more. Also, check out some of the news articles surrounding this "cancer-killing" pill and its promise going forward.

We are always excited to showcase innovative publications utilizing our reagents. We take immense pride in providing researchers and professionals with reliable and consistent products that unlock new possibilities in their fields. Today, we delve into another new study using some of of our primary human brain cells.

Researchers from the University of Nottingham have released two new publications using our primary human brain microvascular endothelial cells (cat. HEC02), brain pericytes (cat. HMP104), and brain astrocytes (cat. HMP202) to build an in vitro blood-brain barrier (BBB) model. Last week, we highlighted the first publication, where the impact of exposure to Substance P (SP) on the BBB was evaluated. You can check out the blog post to learn more.

Image: Astrocytes stained with S100 beta.

Then, to our pleasant surprise, we saw the researchers cited our cells in another BBB related publication. This time, the investigators looked into some of the mechanisms behind neuroinflammation seen in ischaemic stroke and other disorders. They found that inhibition of Rho kinase neutralized the disruptive effects of TNF-α on BBB integrity. You can read the full study here.

Last month, we highlighted the use of our human brain microvascular pericytes (cat. HMP104) and human brain astrocytres (cat. HMP202) in long COVID research (learn more). It didn't take long for the same cells to pop up in another new publication. This time, it's in blood-brain barrier (BBB) research.

Image: HBMECs stained with Claudin-5.

Researchers from the University of Nottingham used our primary human brain microvascular endothelial cells (cat. HEC02), brain pericytes, and brain astrocytes to build an in vitro blood-brain barrier (BBB) model. They wanted to evaluate the impact of exposure to Substance P (SP) on the BBB, finding that “SP promoted a reversible decline” in their model. The findings have implications in neurological disease research among other areas. You can explore the full publication here.

Since the pandemic started, we've seen our reagents used to make important discoveries and observations about the virus. Back in 2021, scientists worked with our Human Small Intestine Endothelial Cells (cat. HEC15) to compare the plasma of healthy patients to those with COVID-19 (learn more). Then, in 2022, researchers infected our Primary Human Neurons (cat. HNC001) with COVID-19 in a publication. They observed the creation of an Alzheimer's-like neuropathology in the formerly healthy neurons (read it here).

Image: Human brain microvascular pericytes stained with VWF/Factor VIII.

Now, preliminary research has just been released looking at the interaction between COVID-19 and HIV. In the citation, the investigators from UNMC and the Karolinska Institutet employed our Human Brain Astrocytes (cat. HMP202) and Human Brain Microvascular Pericytes (cat. HMP104).